The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis

Background. The recommended therapy for patients with chronic hepatitis C (CHC), genotype 1, who have cirrhosis and have failed prior therapy is 12 weeks of sofosbuvir (SOF), ledipasvir (LDV), and ribavirin (RBV). This recommendation is based on expert opinion, and the efficacy of 12 weeks of SOF/LD...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Can J Gastroenterol Hepatol
Autors principals: Stokes, William, Fenton, Carol, Clement, Fiona, James, Matthew, Ronksley, Paul, Tang, Karen L.
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2017
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5358456/
https://ncbi.nlm.nih.gov/pubmed/28367429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/6468309
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars